Seeing Is Believing
Currently out of the existing stock ratings of Peter Lawson, 13 are a SELL (6.28%), 169 are a BUY (81.64%), 25 are a HOLD (12.08%).
Analyst Peter Lawson, currently employed at BARCLAYS, carries an average stock price target met ratio of 60.52% that have a potential upside of 36.5% achieved within 252 days.
Peter Lawson’s has documented 418 price targets and ratings displayed on 42 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MGNX, MacroGenics at 14-May-2025.
Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY) at 9/8/2015. The price target of $103 was fulfilled within 2 days with a profit of $18.62 (22.07%) receiving and performance score of 110.33.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$71
$36.67 (106.82%)
$75
1 months 7 days ago
(01-May-2025)
6/8 (75%)
$40.9 (135.88%)
477
Buy
$57
$22.67 (66.04%)
$55
5 months 30 days ago
(09-Dec-2024)
5/6 (83.33%)
$10.98 (23.86%)
84
Buy
$51
$16.67 (48.56%)
7 months 30 days ago
(09-Oct-2024)
1/1 (100%)
$9.18 (21.95%)
27
Hold
$56
$21.67 (63.12%)
$61
8 months 13 days ago
(26-Sep-2024)
10/13 (76.92%)
$10.39 (22.78%)
223
Hold
$46
$11.67 (33.99%)
$30
11 months 27 days ago
(12-Jun-2024)
4/4 (100%)
$-0.77 (-1.65%)
169
Which stock is Peter Lawson is most bullish on?
Which stock is Peter Lawson is most reserved on?
What Year was the first public recommendation made by Peter Lawson?